The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Diffuse Large B Cell Lymphoma
Related studies linked through entity extraction aliases.
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
- Status
- RECRUITING
- Phase
- PHASE3
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE2
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
- Status
- UNKNOWN
- Phase
- N/A
Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Copanlisib Plus Venetoclax in R/R DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
- Status
- COMPLETED
- Phase
- PHASE1
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
POLA+BR for Relapsed or Refractory DLBCL
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
- Status
- WITHDRAWN
- Phase
- NA
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2